financetom
Business
financetom
/
Business
/
Costco's Market Share Gains Set to Continue, UBS Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Costco's Market Share Gains Set to Continue, UBS Says
Sep 12, 2024 4:42 PM

03:40 PM EDT, 09/12/2024 (MT Newswires) -- Costco Wholesale ( COST ) continues to gain market share with "consistent and robust traffic growth" averaging 6.5% worldwide in recent months, outpacing competitors, UBS said in a note Wednesday.

Costco is expected to report steady revenue growth in fiscal Q4, with projected year-over-year net sales growth of 0.9% and revenue expected to reach $79.7 billion, the investment firm said.

UBS said it projects a 1.2% growth in membership fee income to approximately $1.5 billion, driven by growing membership numbers and executive membership penetration that "likely remained strong as people looked to maximize their spending power" in Q4.

Costco's productivity loop includes reinvesting membership fee income into pricing and is expected to continue to drive traffic and sales growth, the UBS analysts said.

UBS estimates Q4 earnings per share of $5.19 compared with the $5.06 per share consensus of analysts polled by Capital IQ.

UBS maintained a buy rating on Costco with a price target of $940.

Price: 912.85, Change: +12.45, Percent Change: +1.38

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Nurix Therapeutics, Gilead Sciences Extend Research Collaboration By 2 Years
Nurix Therapeutics, Gilead Sciences Extend Research Collaboration By 2 Years
Apr 2, 2024
09:23 AM EDT, 04/02/2024 (MT Newswires) -- Nurix Therapeutics ( NRIX ) said Tuesday that Gilead Sciences ( GILD ) has extended their research collaboration for an additional two years to develop more clinical candidates. Under the terms of the partnership, first signed in 2019, Nurix employs its drug discovery platform to find agents targeting drug degradation via E3 ligases,...
Market Chatter: Amazon Extends Free Credits for Startups to Access AI Models
Market Chatter: Amazon Extends Free Credits for Startups to Access AI Models
Apr 2, 2024
09:23 AM EDT, 04/02/2024 (MT Newswires) -- Amazon.com's ( AMZN ) cloud computing platform Amazon Web Services has extended free credits to startups, allowing them to use major artificial intelligence models like Anthropic and aiming to boost its AI platform Bedrock's market share, Reuters reported Tuesday, citing Amazon Web Services vice president and global head of startups Howard Wright. Other...
Output drops at Kazakhstan's Kashagan oil field - sources
Output drops at Kazakhstan's Kashagan oil field - sources
Apr 2, 2024
MOSCOW, April 2 (Reuters) - Output at the Kashagan oil field, one of Kazakhstan's largest, fell to 30,342 metric tons on April 1 from 52,390 tons a day earlier, two sources familiar with the data told Reuters on Tuesday. An ecological organisation in Kazakhstan said on Tuesday that a large oil spill had been captured by satellite imagery in the...
AstraZeneca, Daiichi Sankyo Say US FDA Accepts Their Biologics License Application for Breast Cancer Treatment
AstraZeneca, Daiichi Sankyo Say US FDA Accepts Their Biologics License Application for Breast Cancer Treatment
Apr 2, 2024
09:25 AM EDT, 04/02/2024 (MT Newswires) -- AstraZeneca ( AZN ) and Daiichi Sankyo said Tuesday the US Food and Drug Administration has accepted their Biologics License Application for datopotamab deruxtecan to treat adult patients with unresectable or metastatic hormone receptor breast cancer. Datopotamab deruxtecan, discovered by Daiichi Sankyo, is being jointly developed by Daiichi Sankyo and AstraZeneca ( AZN...
Copyright 2023-2026 - www.financetom.com All Rights Reserved